Literature DB >> 11032385

Elevated hypothalamic/midbrain serotonin (monoamine) transporter availability in depressive drug-naive children and adolescents.

M Dahlström1, A Ahonen, H Ebeling, P Torniainen, J Heikkilä, I Moilanen.   

Abstract

Cumulative data suggest depression in adulthood being connected to reduced availability of brain serotonin while the role of dopamine remains less specific. Prospective studies have shown a continuity of depressive episodes from childhood to adulthood, combined with poor social function and excess mortality. The object of this study was to examine whether alterations in brain serotonin and/or dopamine transporter levels are already present in depressive children and adolescents. We examined 41 drug-naive patients (aged 7-17) by single photon emission tomography (SPET) using iodine-123-labelled 23-carbomethoxy-3P3(iodophenyl) tropane [123I]beta-CIT as a tracer for monoamine transporters. In addition to the ordinary clinical examination, the patients were given a structured interview and information was gathered from teachers and parents with questionnaires. The diagnoses were established by consensus evaluation between three child psychiatrists. To test the serotonin hypothesis and the dopamine hypothesis regarding depression in children and adolescents, the series was divided into groups with depression present (31) and no depression present (10). In this study, the depressive child and adolescent patients had significantly higher serotonin transporter availability (P < 0.02) in the hypothalamic/midbrain area. Age did not correlate to the hypothalamic/midbrain serotonin transporter binding ratio. No significant difference in dopamine transporter availability in striatum was found between the depressive and the nondepressive children and adolescents.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11032385     DOI: 10.1038/sj.mp.4000766

Source DB:  PubMed          Journal:  Mol Psychiatry        ISSN: 1359-4184            Impact factor:   15.992


  15 in total

1.  Serotonin transporter occupancy induced by paroxetine in patients with major depression disorder: a 123I-ADAM SPECT study.

Authors:  Ana M Catafau; Victor Perez; Pedro Plaza; Juan-Carlos Pascual; Santiago Bullich; Marina Suarez; Maria M Penengo; Iluminada Corripio; Dolors Puigdemont; Monica Danus; Javier Perich; Enric Alvarez
Journal:  Psychopharmacology (Berl)       Date:  2006-10-11       Impact factor: 4.530

2.  High fat diet decreases beneficial effects of estrogen on serotonin-related gene expression in marmosets.

Authors:  Cynthia L Bethea; Arubala P Reddy; Matthew Flowers; Robert A Shapiro; Ricki J Colman; David H Abbott; Jon E Levine
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-12-24       Impact factor: 5.067

3.  Brain serotonin transporter binding, plasma arachidonic acid and depression severity: A positron emission tomography study of major depression.

Authors:  Manesh Gopaldas; Francesca Zanderigo; Serena Zhan; R Todd Ogden; Jeffrey M Miller; Harry Rubin-Falcone; Thomas B Cooper; Maria A Oquendo; Gregory Sullivan; J John Mann; M Elizabeth Sublette
Journal:  J Affect Disord       Date:  2019-07-05       Impact factor: 4.839

4.  Is correction for age necessary in neuroimaging studies of the central serotonin transporter?

Authors:  Swen Hesse; Henryk Barthel; Toshiya Murai; Ulrich Müller; Dominic Müller; Anita Seese; Regine Kluge; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-01-16       Impact factor: 9.236

5.  Extrastriatal binding of [¹²³I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls.

Authors:  Walter Koch; Marcus Unterrainer; Guoming Xiong; Peter Bartenstein; Markus Diemling; Andrea Varrone; John C Dickson; Livia Tossici-Bolt; Terez Sera; Susanne Asenbaum; Jan Booij; Ozlem L Kapucu; Andreas Kluge; Morten Ziebell; Jacques Darcourt; Flavio Nobili; Marco Pagani; Swen Hesse; Thierry Vander Borght; Koen Van Laere; Klaus Tatsch; Christian la Fougère
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-05-08       Impact factor: 9.236

6.  Pretreatment regional brain glucose uptake in the midbrain on PET may predict remission from a major depressive episode after three months of treatment.

Authors:  Matthew S Milak; Ramin V Parsey; Leilani Lee; Maria A Oquendo; Doreen M Olvet; Francoise Eipper; Kevin Malone; J John Mann
Journal:  Psychiatry Res       Date:  2009-05-14       Impact factor: 3.222

7.  Serotonin transporter binding with [123I]beta-CIT SPECT in major depressive disorder versus controls: effect of season and gender.

Authors:  Henricus G Ruhé; Jan Booij; Johannes B Reitsma; Aart H Schene
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-01-30       Impact factor: 9.236

8.  Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender.

Authors:  Maartje M L de Win; Liesbeth Reneman; Johannes B Reitsma; Gerard J den Heeten; Jan Booij; Wim van den Brink
Journal:  Psychopharmacology (Berl)       Date:  2004-01-15       Impact factor: 4.530

9.  Diminished brain 5-HT transporter binding in major depression: a positron emission tomography study with [11C]DASB.

Authors:  Sudhakar Selvaraj; Naga Venkatesha Murthy; Zubin Bhagwagar; Subrata K Bose; Rainer Hinz; Paul M Grasby; Philip J Cowen
Journal:  Psychopharmacology (Berl)       Date:  2009-09-16       Impact factor: 4.530

10.  Increased Brainstem Serotonergic Transporter Availability in Adult Migraineurs: an [(18)F]FP-CIT PET Imaging Pilot Study.

Authors:  Eunkyung Park; Yu Mi Hwang; Min Kyung Chu; Ki-Young Jung
Journal:  Nucl Med Mol Imaging       Date:  2015-10-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.